Hybridize Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 2

Hybridize Therapeutics General Information

Description

Developer of RNA-based therapeutics designed to treat acute and chronic kidney diseases. The company offers kidney-targeted RNA therapies, antisense oligonucleotide treatments, and RNA-based drug development programs for kidney disease and virus-related kidney disorders, enabling medical companies to develop targeted treatments with high specificity for renal conditions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • De Limes 7
  • 2342 DH Oegstgeest
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • De Limes 7
  • 2342 DH Oegstgeest
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hybridize Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 01-Apr-2023 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Jan-2021 Completed Startup
1. Accelerator/Incubator 01-Jan-2018 Completed Startup
To view Hybridize Therapeutics’s complete valuation and funding history, request access »

Hybridize Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hybridize Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Mibiton Venture Capital Minority
Termeer Institute Accelerator/Incubator
To view Hybridize Therapeutics’s complete investors history, request access »

Hybridize Therapeutics FAQs

  • When was Hybridize Therapeutics founded?

    Hybridize Therapeutics was founded in 2018.

  • Where is Hybridize Therapeutics headquartered?

    Hybridize Therapeutics is headquartered in Oegstgeest, Netherlands.

  • What is the size of Hybridize Therapeutics?

    Hybridize Therapeutics has 4 total employees.

  • What industry is Hybridize Therapeutics in?

    Hybridize Therapeutics’s primary industry is Drug Discovery.

  • Is Hybridize Therapeutics a private or public company?

    Hybridize Therapeutics is a Private company.

  • What is Hybridize Therapeutics’s current revenue?

    The current revenue for Hybridize Therapeutics is .

  • Who are Hybridize Therapeutics’s investors?

    Mibiton and Termeer Institute have invested in Hybridize Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process